Kangyuan Medical
康元医疗
Kangyuan Medical (康元医疗) is a biotech company developing next-generation specific bio-adsorption materials based on nanobody technology, founded and led by Wang Yumeng as chairman and CEO . The company sits at the intersection of bioengineering and polymer materials, with two main pipelines: blood purification-specific adsorption columns for conditions including kidney failure, and affinity chromatography media for upstream biopharma applications such as gene therapy and bispecific antibodies . Its first product has entered multi-center GCP clinical trials, with the industrialization path largely established . Dalton Venture (道彤投资) is among its backers, having invested in Kangyuan in 2024 . Related coverage: Dalton Venture's 2025 annual review also noted follow-on investments in companies including Hanuo Medical, Lanji Medical, and Juhuan Technology .
AI-generated — may contain errors, please verify.
Coverage
Steady Steps Toward Renewal, Momentum Into Waves | DTX 2025 Annual Review
Those who walk deeper into the cycle always spot the next beam of light.
A Decade of Dalton, Igniting a New Chapter of Intelligence | Dalton Venture's 2025 Annual Partners Meeting and 10th Anniversary Forum Concludes Successfully
Together, Toward the Brilliance and Distant Horizons of the Next Decade
21st Century Business Herald Interview | Dalton Venture's Sun Qi: Healthcare Is a Long, Snowy Slope — Time for Systematic Bets Is Here
In recent years, as the healthcare industry has yet to emerge from the capital winter, most investment firms have grown more cautious. Dalton Venture, however, has remained active on the investment front thanks to its distinctive strategy and deep understanding of the sector. Recently, **Sun Qi, founding and managing partner of Dalton Venture, sat down with 21st Century Business Herald for an exclusive interview, sharing his unique insights into healthcare industry trends and his confidence and determination to navigate through cycles.**
Spring in Full Bloom, Brilliance Across All Things | Dalton Venture's 2024 CEO Summit Successfully Held
The annual Two Sessions have always been a critical barometer for China's economic trajectory and policy direction. This March, when the government elevated "new quality productive forces" to the top of its work agenda, it sparked intense interest and vigorous debate across industries about this buzzword. As one of the most dynamic drivers of technological innovation and industrial transformation—and a strategic emerging industry that lies at the heart of future industrial planning—how should the medical sector translate new quality productive forces into practice? And where will it steer the development and transformation of the life sciences industry?
New Order, New Positioning, New Engine | Dalton Venture 2023 Annual Partners Meeting Successfully Held
One gathering closes, another horizon opens. Keep exploring the boundless frontier of innovation!
